vs
Side-by-side financial comparison of Ouster, Inc. (OUST) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $62.2M, roughly 1.7× Ouster, Inc.). On growth, Ouster, Inc. posted the faster year-over-year revenue change (106.6% vs 16.9%). Twist Bioscience Corp produced more free cash flow last quarter ($-34.8M vs $-37.2M).
Ouster, Inc. is an American lidar technology company headquartered in San Francisco, California. It builds high-resolution, digital 3D lidar sensors for use in autonomous vehicles, industrial, robotics, drones, mapping, defense, and security systems.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
OUST vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $62.2M | $103.7M |
| Net Profit | — | $-30.5M |
| Gross Margin | 60.2% | 52.0% |
| Operating Margin | 1.5% | -31.7% |
| Net Margin | — | -29.4% |
| Revenue YoY | 106.6% | 16.9% |
| Net Profit YoY | — | 3.4% |
| EPS (diluted) | $0.10 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.2M | $103.7M | ||
| Q3 25 | $39.5M | — | ||
| Q2 25 | $35.0M | — | ||
| Q1 25 | $32.6M | — | ||
| Q4 24 | $30.1M | — | ||
| Q3 24 | $28.1M | — | ||
| Q2 24 | $27.0M | — | ||
| Q1 24 | $25.9M | — |
| Q4 25 | — | $-30.5M | ||
| Q3 25 | $-21.7M | — | ||
| Q2 25 | $-20.6M | — | ||
| Q1 25 | $-22.0M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-25.6M | — | ||
| Q2 24 | $-23.9M | — | ||
| Q1 24 | $-23.8M | — |
| Q4 25 | 60.2% | 52.0% | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 45.2% | — | ||
| Q1 25 | 41.3% | — | ||
| Q4 24 | 43.8% | — | ||
| Q3 24 | 38.3% | — | ||
| Q2 24 | 33.7% | — | ||
| Q1 24 | 28.6% | — |
| Q4 25 | 1.5% | -31.7% | ||
| Q3 25 | -61.4% | — | ||
| Q2 25 | -76.5% | — | ||
| Q1 25 | -73.0% | — | ||
| Q4 24 | -85.1% | — | ||
| Q3 24 | -98.0% | — | ||
| Q2 24 | -93.6% | — | ||
| Q1 24 | -99.5% | — |
| Q4 25 | — | -29.4% | ||
| Q3 25 | -55.0% | — | ||
| Q2 25 | -58.8% | — | ||
| Q1 25 | -67.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -91.1% | — | ||
| Q2 24 | -88.4% | — | ||
| Q1 24 | -91.9% | — |
| Q4 25 | $0.10 | $-0.50 | ||
| Q3 25 | $-0.37 | — | ||
| Q2 25 | $-0.38 | — | ||
| Q1 25 | $-0.42 | — | ||
| Q4 24 | $-0.46 | — | ||
| Q3 24 | $-0.54 | — | ||
| Q2 24 | $-0.53 | — | ||
| Q1 24 | $-0.55 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $208.6M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $261.7M | $456.1M |
| Total Assets | $349.5M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $208.6M | $197.9M | ||
| Q3 25 | $244.5M | — | ||
| Q2 25 | $226.5M | — | ||
| Q1 25 | $168.2M | — | ||
| Q4 24 | $172.0M | — | ||
| Q3 24 | $151.4M | — | ||
| Q2 24 | $184.2M | — | ||
| Q1 24 | $187.8M | — |
| Q4 25 | $261.7M | $456.1M | ||
| Q3 25 | $247.4M | — | ||
| Q2 25 | $221.0M | — | ||
| Q1 25 | $167.9M | — | ||
| Q4 24 | $180.9M | — | ||
| Q3 24 | $171.7M | — | ||
| Q2 24 | $170.6M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $349.5M | $638.1M | ||
| Q3 25 | $353.8M | — | ||
| Q2 25 | $321.8M | — | ||
| Q1 25 | $268.6M | — | ||
| Q4 24 | $276.1M | — | ||
| Q3 24 | $255.2M | — | ||
| Q2 24 | $309.9M | — | ||
| Q1 24 | $317.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.4M | $-24.8M |
| Free Cash FlowOCF − Capex | $-37.2M | $-34.8M |
| FCF MarginFCF / Revenue | -59.8% | -33.5% |
| Capex IntensityCapex / Revenue | 35.0% | 9.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-64.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-15.4M | $-24.8M | ||
| Q3 25 | $-18.3M | — | ||
| Q2 25 | $-1.3M | — | ||
| Q1 25 | $-4.9M | — | ||
| Q4 24 | $-2.6M | — | ||
| Q3 24 | $-3.8M | — | ||
| Q2 24 | $-21.6M | — | ||
| Q1 24 | $-5.7M | — |
| Q4 25 | $-37.2M | $-34.8M | ||
| Q3 25 | $-20.0M | — | ||
| Q2 25 | $-2.2M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $-4.0M | — | ||
| Q3 24 | $-4.3M | — | ||
| Q2 24 | $-22.0M | — | ||
| Q1 24 | $-7.1M | — |
| Q4 25 | -59.8% | -33.5% | ||
| Q3 25 | -50.7% | — | ||
| Q2 25 | -6.3% | — | ||
| Q1 25 | -16.6% | — | ||
| Q4 24 | -13.3% | — | ||
| Q3 24 | -15.4% | — | ||
| Q2 24 | -81.5% | — | ||
| Q1 24 | -27.4% | — |
| Q4 25 | 35.0% | 9.6% | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 2.5% | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 4.8% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | 5.3% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OUST
Segment breakdown not available.
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
